256 related articles for article (PubMed ID: 11926748)
1. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
Tzakis AG
Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
[TBL] [Abstract][Full Text] [Related]
2. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
Zamora MR
Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
[TBL] [Abstract][Full Text] [Related]
3. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.
Snydman DR
Transpl Infect Dis; 2001; 3 Suppl 2():6-13. PubMed ID: 11926753
[TBL] [Abstract][Full Text] [Related]
4. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
7. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
[TBL] [Abstract][Full Text] [Related]
10. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
[No Abstract] [Full Text] [Related]
11. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
13. Delayed-onset primary cytomegalovirus disease after liver transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
[TBL] [Abstract][Full Text] [Related]
14. Role of cytomegalovirus in cardiac allograft vasculopathy.
Weill D
Transpl Infect Dis; 2001; 3 Suppl 2():44-8. PubMed ID: 11926750
[TBL] [Abstract][Full Text] [Related]
15. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
17. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
18. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.
Weill D; Lock BJ; Wewers DL; Young KR; Zorn GL; Early L; Kirklin JK; McGiffin DC
Am J Transplant; 2003 Apr; 3(4):492-6. PubMed ID: 12694074
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
